FDA Oncologic Drugs Advisory Committee recommends Carvykti (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma – Johnson & Johnson
Johnson & Johnson announced that the FDA Oncologic Drugs Advisory Committee (ODAC) recommends Carvykti (ciltacabtagene autoleucel, cilta-cel) for the treatment of adult patients with relapsed or refractory multiple… read more.
